Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II study evaluating Debio 1347 in Advanced Solid Tumors harboring an FGFR fusion (PHOTO)

Lausanne, Switzerland (ots) -

Patients will be recruited in North America, Europe, South
America and the Asia Pacific region.

Debiopharm International SA (Debiopharm -
www.debiopharm.com/debiopharm-international/), part of Debiopharm
Group(TM), a Swiss-based global biopharmaceutical company, today
announced the start of FUZE, a clinical phase II study to evaluate
Debio 1347 for the treatment of solid tumors harboring an FGFR fusion
(NCT03834220).

The presence of a specific alteration of the fibroblast growth
factor receptor (FGFR) genes - called a fusion - deregulates FGFR
signaling pathways and drives cancer growth. Debio 1347 is a potent
selective inhibitor of FGFRs.

This study will enroll patients with advanced or metastatic tumors
whose cells show specific FGFR gene alterations, namely FGFR1, FGFR2
or FGFR3 gene fusions. The purpose of the trial is to demonstrate
that Debio 1347 can bring clinical benefit to patients with tumors
harboring an FGFR fusion.

"Historically, cancer therapies have been approved for use on the
basis of the tumor's location and stage of cancer. The FUZE clinical
trial has been designed on the basis of a specific tumor's genetic
alteration, rather than its location. This tissue-agnostic approach
could therefore benefit cancer patients with a rare genetic
alteration, such as an FGFR fusion, irrespective of tumor type. We
are committed to using innovative treatment approach guided by
advanced technologies to meet unmet needs with the intent to improve
outcomes and quality of life for cancer patients". - Claudio Zanna,
Group Medical Director at Debiopharm International SA

About Debio 1347

Debio 1347 is an investigational novel orally available small
molecule highly selective FGFR 1, 2, 3 ATP competitive inhibitor.
Results from the phase 1 clinical trial showed that patients with
solid tumors with activating alterations in FGFR may benefit from
treatment with Debio 1347. Debio 1347 is expected to become a
tailored treatment which will be developed with a companion
diagnostic.

For more information:
https://patients.debiopharm.com/genetic-alterations/

About Debiopharm International SA

Part of Debiopharm Group(TM), Debiopharm International SA is
focused on the development of prescription drugs that target unmet
medical needs. The company in-licenses and develops promising drug
candidates. The products are commercialized by pharmaceutical
out-licensing partners to give access to the largest number of
patients worldwide. For more information, please visit
www.debiopharm.com/debiopharm-international/

We are on Twitter. Follow us @DebiopharmNews at
http://twitter.com/DebiopharmNews

Pressekontakt:
Debiopharm International SA
Contact
Christelle von Büren
Communication Coordinator
christelle.vonburen@debiopharm.com
Tel: +41 (0)21 321 01 11

Original-Content von: Debiopharm International SA, übermittelt durch news aktuell